SCHEMBL974911

SCHEMBL974911

C=CCNS(=O)(=O)NCC=C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
CA1 P00915 3/20 0.35
CA12 O43570 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 1/20 0.35
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HIF1A Q16665 1/20 0.33
MAPT P10636 1/20 0.33
CA7 P43166 1/20 0.32
CA14 Q9ULX7 1/20 0.32
KMT2A Q03164 2/20 0.31
GAA P10253 1/20 0.31
MEN1 O00255 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8835411 0.84
SCHEMBL4793302 0.81
SCHEMBL6223484 0.79
SCHEMBL17891350 0.78 TSHR (0.32) TSHRMAPK1
SCHEMBL10832324 0.77
SCHEMBL6894366 0.77
SCHEMBL1158383 0.77
SCHEMBL44498 0.77
SCHEMBL2840847 0.77
SCHEMBL170003 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023071998-A1 NOVEL PYRIDO OR TRIAZINE-SUBSTITUTED PYRIDO HETEROCYCLIC COMPOUND 杭州德睿智药科技有限公司 2023-05-04 WO claimed
WO-2018026812-A1 ANTIVIRAL AGENTS OHIO STATE INNOVATION FOUNDATION (US) 2018-02-08 WO claimed
WO-2018026811-A2 ANTIFUNGAL AGENTS OHIO STATE INNOVATION FOUNDATION (US) 2018-02-08 WO claimed
WO-2012113920-A1 ARYLSULFONE DERIVATIVES WITH ACTIVITY AGAINST HUMAN BETAHERPESVIRUSES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-08-30 WO claimed
EP-1676846-B1 Hydantoin derivatives as MMP inhibitors ASTRAZENECA AB (SE) 2010-12-29 EP claimed
US-20080306065-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-12-11 US claimed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US claimed
CN-101273157-A Zinc-nickel alloy electroplating system PAVCO INC (US) 2008-09-24 CN claimed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US claimed
WO-2007002070-A2 ZINC-NICKEL ALLOY ELECTROPLATING SYSTEM PAVCO, INC. (US) 2007-01-04 WO claimed
WO-2002074749-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO claimed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO claimed
WO-2002074767-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO claimed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO claimed
WO-2002074748-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO claimed
US-6291045-B1 SUBSTRATES WITH DYE LAYER WITH TRIMETHINE CYANINE DYES, RECORDING AND READING, TREATMENT WITH LASER BEAM AND ULTRAVIOLET RADIATION TAIYO YUDEN CO., LTD. (JP) 2001-09-18 US claimed
US-6218072-B1 CONTAINING CYANINE DYE TAIYO YUDEN CO., LTD. (JP) 2001-04-17 US claimed
US-5976658-A CONTAINING TRIMETHINE-CYANINE DYE; RECORDING USING LASER TAIYOYUDEN CO., LTD. (JP) 1999-11-02 US claimed
EP-0919998-A1 Optical information recording medium TAIYO YUDEN CO., LTD. (JP) 1999-06-02 EP claimed
EP-0840307-A2 Optical information recording medium Taiyoyuden Co., Ltd. (JP) 1998-05-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306065-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 TSHR 4080/4885ALDH1A1 612/4885CA1 93/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 TSHR 2145/4885ALDH1A1 1381/4885CA1 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.